A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis
Latest Information Update: 27 Jan 2023
Price :
$35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 20 Jan 2023 Planned End Date changed from 31 Dec 2022 to 7 Dec 2023.
- 20 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 7 Dec 2023.
- 12 Apr 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.